Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07113691 · ClinicalTrials.gov registry record · Phase 1
Iadademstat + SBRT With Atezo in ES-SCLC
A Phase 1 study of Extensive Stage Small Cell Lung Cancer (ES-SCLC), sponsored by Yale University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT07113691: Recruiting Phase 1 study of Extensive Stage Small Cell Lung Cancer (ES-SCLC), sponsored by Yale University.
NCT07113691 is a Phase 1 study of Extensive Stage Small Cell Lung Cancer (ES-SCLC) that is actively recruiting participants, run by Yale University. The registered enrollment target is 15 participants, below the 315-participant average among 3 other Extensive Stage Small Cell Lung Cancer (ES-SCLC) trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07113691, a Phase 1 study of Extensive Stage Small Cell Lung Cancer (ES-SCLC), is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 1b dose escalation, open-label, non-randomized study of participants with residual, progressive or recurrent ES-SCLC who previously received platinum-based chemotherapy with or without immune checkpoint inhibitor therapy; participants who have achieved only stable disease at the completion of initial platinum-based treatment are eligible for enrollment.
Primary Outcome
The number of participants experiencing dose-limiting toxicities (DLTs) during the study period will be recorded, providing a measure of how frequently DLTs occur when iadademstat is combined with atezolizumab and SBRT.
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG Iadademstat
- RADIATION SBRT
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-01-20 |
| Est. Completion | 2030-01 |
| Phase | Phase 1 |
What NCT07113691 shows while recruiting
NCT07113691 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 315-participant average among 3 other Extensive Stage Small Cell Lung Cancer (ES-SCLC) trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Extensive Stage Small Cell Lung Cancer (ES-SCLC) appearing as the primary indexed condition, and to 3 interventions - of which Atezolizumab is the first listed.
NCT07113691 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT07113691 about?
NCT07113691 is a clinical study titled "Iadademstat + SBRT With Atezo in ES-SCLC". This is a phase 1b dose escalation, open-label, non-randomized study of participants with residual, progressive or recurrent ES-SCLC who previously received platinum-based chemotherapy with or without immune checkpoint inhibitor therapy; participants who have achieved only stable disease at the comp...
What is the current status of trial NCT07113691?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2026-01-20. Estimated completion is 2030-01.
What conditions does trial NCT07113691 study?
This clinical trial studies the following conditions: Extensive Stage Small Cell Lung Cancer (ES-SCLC).
What interventions are being tested in trial NCT07113691?
The interventions under investigation include: Atezolizumab (DRUG), Iadademstat (DRUG), SBRT (RADIATION).
Who is sponsoring clinical trial NCT07113691?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07113691 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
SG and Immunotherapy as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer
RECRUITING · Phase 2
-
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI